Company Filing History:
Years Active: 1991-1995
Title: The Innovative Contributions of Bryan M Longenecker
Introduction
Bryan M Longenecker is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of medical technology, particularly in the development of monoclonal antibodies for diagnostic and therapeutic applications. With a total of 2 patents, his work has the potential to impact cancer detection and treatment.
Latest Patents
Longenecker's latest patents include groundbreaking innovations in the use of monoclonal antibodies. One patent focuses on carcinoma-marking monoclonal antibodies elicited with synthetic antigens. These antibodies are useful as carcinoma markers and can be tagged with radiometals or radiohalogens for radioimmunoimaging. The radiolabeled monoclonal antibody 155H.7, elicited by this antigen, demonstrates its utility as a tumor imaging agent by rapidly localizing and persisting in tumor tissues. Another patent describes a method for detecting blood platelets using the labeled monoclonal antibody 50 H.19. This method allows for the detection and localization of thrombi, emboli, and other medical conditions, showcasing the versatility of his inventions.
Career Highlights
Throughout his career, Longenecker has worked with several prominent companies, including Summa Medical Corporation and Biomira, Inc. His experience in these organizations has contributed to his expertise in the field of medical innovations.
Collaborations
Longenecker has collaborated with notable professionals in his field, including Antoine A Noujaim and Connie J Turner. These collaborations have likely enriched his research and development efforts.
Conclusion
Bryan M Longenecker's contributions to the field of medical technology through his innovative patents highlight his role as a significant inventor. His work in monoclonal antibodies has the potential to advance cancer diagnostics and treatment, making a lasting impact in the medical community.